Quick answer
How should longevity research peptide stacks be evaluated? A stack is a hypothesis that two or more pathways interact, so it should be judged by whether the pathways are distinct, whether single-agent controls exist and whether the combination can be kept chemically stable. In the V8 catalog the longevity-relevant combinations are GHK-Cu with KPV, the Glow stack (GHK-Cu, BPC-157, TB-500), the KLOW stack (GHK-Cu, KPV, BPC-157, TB-500) and a NAD+ with MOTS-c blend that the site lists as coming soon. Each pairs a different set of pathways. The table below maps combination to pathway so a design can start from the question rather than the product name.
This guide is about combination design. The companion topic of what longevity research means at the single-compound level, including telomerase, mitochondrial and NAD+ biology, is covered in the NAD research overview and the MOTS-c research overview. Here the question is narrower: when does combining compounds make experimental sense, and what must be controlled when it does? For laboratory research use only; not for human consumption.
Combinations in the catalog and the pathways they pair
| Combination | Components | Pathways paired | Size on page |
|---|---|---|---|
| GHK-Cu + KPV | Copper tripeptide, alpha-MSH C-terminal tripeptide | Copper-peptide signaling and melanocortin-fragment signaling | 60 mg total vial |
| Glow stack | GHK-Cu, BPC-157, TB-500 | Matrix and cell-signaling pathways | 70 mg total (50 / 10 / 10) |
| KLOW stack | GHK-Cu, KPV, BPC-157, TB-500 | Combined extracellular-matrix and cell signaling, plus melanocortin models | 80 mg blend |
| NAD+ + MOTS-c | NAD+ coenzyme, MOTS-c peptide | AMPK pathway and NAD+ redox metabolism | 400 mg / 20 mg; listed as coming soon |
The pairing logic differs. The first three sets combine matrix and signaling pathways, which in dermal and tissue cell models can be read together. The NAD+ and MOTS-c pair combines an energy-metabolism coenzyme with a mitochondrial-derived peptide, which is a different question altogether. The relationships between the multi-compound products are discussed in Glow versus KLOW versus Wolverine, the KLOW stack explained and the NAD+ and MOTS-c blend explained.
Starting from the hallmark, not the product
The hallmarks-of-aging framework (López-Otín and colleagues, 2023) separates mitochondrial dysfunction, altered intercellular communication, deregulated nutrient sensing and other processes, and the geroscience argument (Kennedy and colleagues, 2014) is that they interact. A stack is a way to examine one interaction. Pick it by naming the two processes and the cell system in which both can be measured:
| Interaction hypothesis | Possible pairing | Cell system | Joint readout |
|---|---|---|---|
| Redox state and AMPK signaling | NAD+ with MOTS-c | Myotubes or hepatocyte lines | NAD+/NADH ratio with AMPK phosphorylation |
| Matrix remodeling and melanocortin-derived signaling | GHK-Cu with KPV | Dermal fibroblasts, keratinocytes | Matrix output with inflammatory-marker expression |
| Matrix remodeling and cell migration | GHK-Cu with BPC-157 and TB-500 | Scratch assay in dermal cells | Migration rate with matrix-gene expression |
| Mitochondrial peptide and nutrient-sensing | MOTS-c alone with glucose or nutrient variation | Cultured cells in defined media | Uptake and respiration |
The last row is a reminder that some of the strongest designs do not combine two compounds at all; they combine one compound with a changed condition. MOTS-c was described by Lee and colleagues (2015) as acting on metabolic homeostasis through the AMPK pathway, and that framing lends itself to nutrient-variation experiments. NAD+ is a cofactor for sirtuins, discussed by Imai (2016); anything that changes NAD+ availability can in principle change sirtuin readouts, which is an argument for a vehicle-matched NAD+ control. Pathway reading for both is in MOTS-c and the AMPK pathway.
What makes a stack scientifically sound
- Distinct pathways. If two compounds act on the same pathway, a combination tells you little beyond dose response.
- Single-agent arms in the same run. A combination result needs the component curves from the same plate or experiment.
- A pre-chosen reference model. Chou (2006) set out the combination-index approach and Foucquier and Guedj (2015) compare other models; choose one before looking at the data.
- Molar reporting. Convert each component to molarity with its own molecular weight; a milligram ratio between a coenzyme of about 660 Da and a peptide of a few kDa says little about stoichiometry.
- Stability in the mix. Check by HPLC that each component survives in the shared solution for the planned storage time.
- Independent replicates. Biological replicates, not repeated wells.
A worked example: matrix signaling plus melanocortin signaling
Consider a dermal fibroblast experiment built around the GHK-Cu and KPV pairing. The GHK-Cu and KPV product description frames the use as examining copper-peptide signaling and melanocortin-derived tripeptide signaling in the same experiment and comparing against each component alone. A minimal plate carries six groups: vehicle; GHK-Cu alone; KPV alone; the fixed-ratio mixture; a copper-free GHK arm; and a copper-only arm. Each group is run at a log-spaced series of at least five concentrations, expressed as molarity of each component, in three independent biological replicates. The endpoints are one matrix readout (for example hydroxyproline or a collagen-type immunoassay) and one signaling readout (for example a cytokine transcript panel), measured at the same time point. The analysis compares the mixture with the reference predicted from the single-agent curves, using the reference model fixed in advance.
Two things distinguish this from a casual mix. The copper-free and copper-only arms make sure that any difference can be attributed to the peptide, the metal or the pairing. And the readouts belong to two different pathways, so the design can detect whether the compounds act independently, which is the null hypothesis, or interact. Background on the individual components is in the GHK-Cu overview, the KPV overview and the GHK-KPV overview, and a related comparison is GHK-Cu versus KPV.
Reading published stack claims
| Claim pattern | What to ask |
|---|---|
| "Works synergistically" | Which reference model, and were single-agent curves in the same experiment? |
| "Supports longevity" | Which hallmark, which assay and which model system was measured? |
| "Optimized ratio" | Optimized against what endpoint, and was a ratio series actually tested? |
| "Clinically studied combination" | Not applicable to research-use compounds; ask for the primary source and what species and system it used |
| "Pure and stable blend" | Is there a lot document, and were the components checked for stability together? |
A habit worth adopting is to restate every claim in the form "in system X, readout Y changed by Z under conditions C." Any claim that cannot be restated that way is marketing language and should not be carried into a protocol.
Fixed blends versus building your own
A pre-blended vial removes one source of variability, because every replicate draws from the same mixture and the ratio is constant; the trade-off is that the ratio cannot be varied, and single-compound vials are still needed for single-agent arms. A self-built mixture permits a ratio series but adds a handling step and the risk of mixing error. Many laboratories use both: the blend for the headline comparison and individual vials for the controls and for ratio-response work. In either case, the lot numbers and preparation dates of all vials belong in the same record, together with the storage temperature and the number of times each vial was opened, because those details explain most unexplained differences between repeated experiments.
Chemistry that limits stacks
Combinations are constrained by what their components do to one another in solution. A copper complex mixed with peptides that carry free thiols, imidazole or methionine can change the oxidation state of those residues; the topic is examined in does copper degrade other peptides in a blend. NAD+ is a dinucleotide with different pH and temperature sensitivity from a peptide, so the optimal pH for one may not suit the other. For any blend, dissolve the components separately first, then combine, and check by HPLC. The general design logic is covered in peptide blends and research stacks and Glow stack versus individual peptides.
Documentation and handling
Each product page lists a lyophilized powder with refrigeration at 2–8 °C, −20 °C for long-term storage and protection from heat, moisture and light; the NAD+ and MOTS-c blend is not yet on sale, so use the single-compound pages (MOTS-c and NAD+) for now. For lot documents, where published, check the COA library. Per-component concentration is mass divided by diluent volume; the calculator converts units for any listed total mass and ratio. A broader catalog is at the shop.
Frequently asked questions
What is a longevity research stack?
A combination of two or more compounds studied together to examine how pathways relevant to aging biology interact, such as matrix remodeling with melanocortin signaling or NAD+ redox metabolism with AMPK signaling.
Which combinations does V8 list?
GHK-Cu with KPV, the Glow stack (GHK-Cu, BPC-157, TB-500) and the KLOW stack (GHK-Cu, KPV, BPC-157, TB-500) are listed products. NAD+ with MOTS-c is listed as coming soon.
Is a bigger stack better?
Not by default. Every additional component adds variables and requires more control arms. A well-designed two-component experiment is often more informative than a four-component mix.
Why must single-agent arms be run alongside a combination?
Interaction is defined relative to what each component does alone. Without single-agent curves from the same experiment, synergy or antagonism cannot be judged.
Why report stacks in moles?
Different components have very different molecular weights, so equal masses are not equal numbers of molecules. Molar reporting makes ratios meaningful.
Can copper peptides be mixed with other peptides safely?
Not automatically. Copper can interact with residues such as methionine, cysteine and histidine, so stability in the mixture should be confirmed by HPLC.
Is NAD+ a peptide?
No. It is a dinucleotide coenzyme. That is why it is handled and analyzed differently from MOTS-c and the other peptides.
How many concentrations should a combination experiment use?
At least five log-spaced concentrations per single agent and for the mixture, so that a curve can be fitted. A single concentration cannot distinguish synergy from a shifted dose response.
What should be recorded for every stack vial?
Lot numbers, the date and diluent used for reconstitution, the order of addition if mixed in the lab, the storage condition and every freeze-thaw event, so that results can be traced back to the exact material.
Are any of these results about effects in people?
No. The material describes laboratory experimental design for research use only.
How should the vials be stored?
The product pages state refrigeration at 2–8 °C, −20 °C for long-term storage and protection from heat, moisture and light.
Related reading: Research Peptide Stacks: How to Read a Blend Label, Research Peptide Supplier Checklist: 10 Things to Verify, How to Choose Research Peptides in 2026: By Question.
References
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001
- Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-713. doi:10.1016/j.cell.2014.10.039
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
- Imai S. It takes two to tango: NAD+ and sirtuins in aging/longevity control. NPJ Aging Mech Dis. 2016;2:16017. doi:10.1038/npjamd.2016.17
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681. doi:10.1124/pr.58.3.10
- Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149. doi:10.1002/prp2.149
